Literature DB >> 34999809

Does preoperative dual antiplatelet therapy affect bleeding and mortality after total arch repair for acute type A dissection?

Fu-Cheng Xiao1, Wei-Guo Ma1, Yi-Pen Ge1, Jun-Ming Zhu1, Li-Zhong Sun1.   

Abstract

OBJECTIVES: Data are scarce and mixed regarding the impact of preoperative dual antiplatelet therapy (DAPT) on the surgical outcomes of acute type A aortic dissection (ATAAD). We seek to evaluate the impact of DAPT on bleeding-related events and early- and mid-term mortality after total arch replacement and frozen elephant trunk in such patients.
METHODS: This study comprised 48 ATAAD patients on preoperative DAPT and 418 without DAPT (the whole series, i.e. unmatched cohort), from which 45 matched pairs were selected by propensity score (matched cohort). Bleeding-related events (reoperation for bleeding, bleeding of ≥1500 ml within the first 12 h postoperatively or transfusion of ≥10 units of red blood cell or use of recombinant activated factor VII), operative mortality and mid-term survival were compared in the unmatched and matched cohorts. The impact of preoperative DAPT was evaluated with multivariable analysis.
RESULTS: In the unmatched cohort, bleeding of ≥1500 ml/12 h postoperatively was more common in the DAPT group (18.8% vs 8.4%, P = 0.020); operative mortality was 9.7%, which did not differ with DAPT (12.5% vs 9.3%, P = 0.48). Nor did bleeding-related events (54.2% vs 43.5%, P = 0.16) differ significantly between 2 groups. In the matched cohort, neither were drainage of ≥1500 ml/12 h (20% vs 6.7%, P = 0.063) and bleeding-related events (53.3% vs 42.2%, P = 0.30), nor operative mortality (13.8 vs 8.9%, P = 0.50) and mid-term survival (79.3% vs 76.4%, P = 0.93) significantly different between 2 groups. DAPT was not identified as a predictor for operative mortality [odd ratio (OR) 0.97, 95% confidence interval (CI) 0.31-3.08; P = 0.96; adjusted OR 1.28, 95% CI 0.22-7.20; P = 0.78] and bleeding-related events (OR 1.50, 95% CI 0.76-2.95; P = 0.24; adjusted OR 2.03, 95% CI 0.80-3.66; P = 0.14).
CONCLUSIONS: In patients with ATAAD undergoing total arch replacement and frozen elephant trunk, although preoperative DAPT led to more postoperative bleeding, it did not increase bleeding-related events nor operative mortality nor mid-term death. The results of this study imply that for patients with ATAAD, emergency surgical repair, even if as extensive as total arch repair, should not be contraindicated or delayed simply because of ongoing DAPT.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Antiplatelet therapy; Aortic dissection; Bleeding; Mortality; Outcomes; Surgery

Mesh:

Substances:

Year:  2021        PMID: 34999809      PMCID: PMC8923404          DOI: 10.1093/icvts/ivab226

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  27 in total

1.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Authors:  Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

2.  Limited versus extended repair for acute type A aortic dissection: long-term outcomes of the Beijing approach beyond 10 years.

Authors:  Wei-Guo Ma; Yu Chen; Wei Zhang; Qing Li; Jian-Rong Li; Jun Zheng; Yong-Min Liu; Jun-Ming Zhu; Li-Zhong Sun
Journal:  J Cardiovasc Surg (Torino)       Date:  2020-02-18       Impact factor: 1.888

3.  Reversal of heparin after cardiac surgery: protamine titration using a statistical model.

Authors:  Fredrik Ödling Davidsson; Daniel Johagen; Micael Appelblad; Staffan Svenmarker
Journal:  J Cardiothorac Vasc Anesth       Date:  2014-12-08       Impact factor: 2.628

4.  Epidemiology and clinicopathology of aortic dissection.

Authors:  I Mészáros; J Mórocz; J Szlávi; J Schmidt; L Tornóci; L Nagy; L Szép
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

5.  Total arch replacement and frozen elephant trunk for aortic dissection in aberrant right subclavian artery.

Authors:  Jian-Rong Li; Wei-Guo Ma; Yu Chen; Jun-Ming Zhu; Jun Zheng; Shang-Dong Xu; Yong-Min Liu; Li-Zhong Sun
Journal:  Eur J Cardiothorac Surg       Date:  2020-07-01       Impact factor: 4.191

Review 6.  Coagulation disturbance in profound hypothermia: the influence of anti-fibrinolytic therapy.

Authors:  S Westaby
Journal:  Semin Thorac Cardiovasc Surg       Date:  1997-07

7.  Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study.

Authors:  Cristina E Firanescu; Elisabeth J Martens; Jacques P A M Schönberger; Mohamed A Soliman Hamad; Albert H M van Straten
Journal:  Eur J Cardiothorac Surg       Date:  2009-07-17       Impact factor: 4.191

8.  Can Frozen Elephant Trunk Cure Type I Dissection Confined to Thoracic Aorta in Marfan Syndrome?

Authors:  Yu Chen; Wei-Guo Ma; Jian-Rong Li; Jun Zheng; Qing Li; Yong-Min Liu; Jun-Ming Zhu; Li-Zhong Sun
Journal:  Ann Thorac Surg       Date:  2019-09-05       Impact factor: 4.330

9.  Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.

Authors:  A Bertling; A C Fender; L Schüngel; M Rumpf; K Mergemeier; G Geißler; W Sibrowski; R Kelsch; J Waltenberger; J A Jakubowski; B E Kehrel
Journal:  J Thromb Haemost       Date:  2018-04-23       Impact factor: 5.824

Review 10.  Universal definition of perioperative bleeding in adult cardiac surgery.

Authors:  Cornelius Dyke; Solomon Aronson; Wulf Dietrich; Axel Hofmann; Keyvan Karkouti; Marcel Levi; Gavin J Murphy; Frank W Sellke; Linda Shore-Lesserson; Christian von Heymann; Marco Ranucci
Journal:  J Thorac Cardiovasc Surg       Date:  2013-12-09       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.